Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits
Open accessThe DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index; 79 of the 180 sources its claims cite were checked for support.
Abstract
The legalization of cannabis for medical and recreational purposes has progressed internationally. Chronic patterns of cannabis use have been associated with disrupted learning, impaired cognitive performance, reduced educational attainment, cannabis use disorder, psychosis/schizophrenia, mood and anxiety disorders, and suicidal behaviors among adolescents and young adults.
Overview
CoChat Summary
TL;DR
This 2024 review summarizes evidence that recreational cannabis use, especially frequent high-THC use, is linked to acute impairment and several longer-term mental and physical health risks, while medical cannabinoid benefits are limited to a few indications. The strongest therapeutic evidence is for CBD in refractory epilepsy, with smaller benefits for spasticity, chronic pain, and chemotherapy-induced nausea/vomiting.
Key findings
- The review states that regular use of high-THC products can produce cannabis use disorder (CUD), and that 22% of people who ever use cannabis meet criteria for CUD, rising to 33% among weekly or daily users.
- Acute consumption of high THC doses can cause time-limited mental, gastrointestinal, and cardiovascular problems and motor vehicle accidents; the paper reports traffic-accident odds ratios ranging from 1.25 to 1.97.
- For psychosis, meta-analyses found a robust association with cannabis use and a dose–response relationship; one multinational study reported that daily use of high-potency cannabis increased psychosis risk fivefold versus non-users, while daily low-potency use doubled risk.
- For medicinal use, the paper says cannabinoids have small beneficial effects for muscle spasticity, limited/inconsistent evidence for chronic pain, higher antiemetic effects than placebo or conventional anti-emetics for CINV, and that CBD is moderately efficacious for refractory epilepsy in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.
Methods
- The paper is a selective literature review intended to update a prior systematic literature search on “benefits and risks of cannabinoids” commissioned by the German Ministry of Health.
- Searches were conducted in PubMed and the Cochrane Central Register of Clinical Trials for 10.5.2016 to 10.5.2023, prioritizing systematic reviews and meta-analyses from the past decade; when unavailable, the authors included strong, adequately powered studies published since the most recent review.
- The references of included studies were screened for additional relevant studies, and the authors used the causal-inference approach outlined in their Text Box 1.
Limitations
- The authors explicitly note that the literature is sparse for some questions, including increased cannabis potency and its effects, and that more rigorous data is needed on outcomes associated with potency, product diversity, and new routes of administration.
- They state that confounding by tobacco and other drug use complicates interpretation of long-term harms, and that case-control and cohort studies are subject to unmeasured confounding.
- Evident from the text: the review is selective rather than a full systematic review of all cannabis evidence, and much of the therapeutic literature is described as limited, heterogeneous, or insufficient for guidance.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
68 Valid · 3 Not valid · 68 Not checked · 39 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Acute cannabis consumption has consistently been associated with a modest increase in the risk of traffic accidents, with odd ratios ranging from 1.25 to 1.97 [17].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Partly supportedcites [17] Preuss UW, Huestis MA, Schneider M et al (2021) Cannabis use and car crashes: a review. Front Psychiatry 12:643315. https://doi.org/10.3389/fpsyt.2021.643315 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says acute cannabis use increases car-crash risk and describes the increase in meta-analytic odds ratios as slight. The Results of Meta-Analyses (page unavailable) report an adjusted OR of 1.25 and an OR of 1.97 for the blood-analysis subgroup, but do not present 1.25–1.97 as the overall range; other reported estimates exceed it. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, there are no reliable cut-off values for blood THC levels that indicate when an individual is impaired.”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Supportedcites [24] Pearlson GD, Stevens MC, D’Souza DC (2021) Cannabis and driving. Front. Psychiatry 12:689444. https://doi.org/10.3389/fpsyt.2021.689444 source
The Discussion (page not provided) says there is no straightforward way to equate blood THC levels with current driving impairment. The Recommendations likewise say that detectable blood THC levels are not a useful standard and that meaningful thresholds lack evidence-based consensus. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Growing evidence indicates that dysregulation of ECS may contribute to brain dysfunction, psychopathology, neurodevelopmental problems, neurodegenerative diseases, neuroinflammation, among other physiological functions [9, 10].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Introduction
What the sources say
- Partly supportedcites [9] Lu HC, Mackie K (2016) An introduction to the endogenous cannabinoid system. Biol Psychiatry 79(7):516–525. https://doi.org/10.1016/j.biopsych.2015.07.028 sourceExperimental — accuracy not yet measured
The Introduction links ECS perturbations to psychiatric disorders, and the LTD section suggests that disrupted cannabinoid signaling could contribute to developmental abnormalities. The Endocannabinoid degradation section links loss of an enzyme involved in endocannabinoid metabolism to a neurodegenerative syndrome. The Cannabinoid receptors section describes changes in CB2 expression during inflammation, but does not establish that ECS dysregulation contributes to neuroinflammation. Page numbers were not available in our copy. (LLM, conf=0.84)
- Partly supportedcites [10] Lowe H, Toyang N, Steele B, Bryant J, Ngwa W (2021) The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci 22(17):9472. https://doi.org/10.3390/ijms22179472 sourceExperimental — accuracy not yet measured
The Introduction (§1.1; page unavailable) links the ECS to nervous function, neurogenesis, pre- and post-natal development, and neuropsychological and neurodegenerative diseases. The Neurological/Neurodegenerative Diseases section (§3; page unavailable) also implicates the ECS in neurological pathology and describes cannabinoid modulation of neuroinflammation. The paper does not establish that ECS dysregulation contributes to every listed outcome, particularly neurodevelopmental problems or neuroinflammation. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Research is showing that there are some individuals who use cannabis to reduce symptoms of mood or anxiety disorders [40].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Supportedcites [40] Beletsky A, Liu C, Lochte B, Samuel N, Grant I (2024) Cannabis and anxiety: a critical review. Med Cannabis Cannabinoids 7(1):19–30. https://doi.org/10.1159/000534855 source
The Introduction’s table reports that people with lifetime depression used cannabis for self-medication and that some chronic users reported anxiety-related symptom relief. It also states that cannabis is used by some chronic users seeking to alleviate anxiety. This supports the claim about why some individuals use it, without establishing that it effectively treats those disorders. (LLM, conf=0.91)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There is partial support from longitudinal studies for a causal link between cannabis use and a reduction in motivation, that has been referred to as an “a motivation syndrome” [31].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Supportedcites [31] Pacheco-Colón I, Limia JM, Gonzalez R (2018) Nonacute effects of cannabis use on motivation and reward sensitivity in humans: a systematic review. Psychol Addict Behav 32(5):497–507. https://doi.org/10.1037/adb0000380 source
The Discussion concludes that two longitudinal studies provide evidence of a causal relationship between cannabis use and reduced motivation and reward sensitivity. It also describes the broader evidence for an “amotivational syndrome” as equivocal, consistent with the citing sentence’s qualified wording. (LLM, conf=0.94)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
124 more claims · 46 with their cited sources checked
Create a free account to see all 178 claims and to verify the 18 references still open.
- It may state two separate claims as one. 40
- Probably not a substantial claim. 13
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
(2012) · SpringerReference · doi:10.1007/springerreference_121117 · Cited by 20,570
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
(2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/103.1437-1588 · Cited by 11,796
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
International Statistical Classification of Diseases and Related Health Problems
(2011) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-0-387-79948-3_3055 · Cited by 4,151
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169 · cited 4×
“Mild to moderate central nervous or gastro-intestinal side effects are more common with cannabinoids than with placebo but severe side effects are rare [13].”
InfluentialNeurobiologic advances from the brain disease model of addiction
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1511480 · Cited by 2,008 · cited 1×
“Case–control neuroimaging studies of the brain with high-resolution provide early evidence for altered brain integrity in brain regions with a high density of CB1 receptors in heavy cannabis users [75].”
Self-citationDegenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A., Whiteford, H., Leung, J., Naghavi, M., Griswold, M., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30337-7 · Cited by 1,572 · cited 1×
“Worldwide, 22 million people are estimated to meet criteria for CUD, similar in number to opioid use disorders (27 million people) [56].”
Self-citationInternational statistical classification of diseases and related health problems. Tenth revision.
Brämer, G. R. (1988) · PubMed · Cited by 1,492
Groce, E. (2018) · Journal of Medical Regulation · doi:10.30770/2572-1852-104.4.32 · Cited by 1,330
An Introduction to the Endogenous Cannabinoid System
Lu, H.-C., & Mackie, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.028 · Cited by 1,234 · cited 1×
“Growing evidence indicates that dysregulation of ECS may contribute to brain dysfunction, psychopathology, neurodevelopmental problems, neurodegenerative diseases, neuroinflammation, among other physiological functions [9, 10].”
Gobbi, G., Atkin, T., Zytynski, T., Wang, S., Askari, S., Boruff, J., Ware, M., Marmorstein, N., Cipriani, A., Dendukuri, N., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4500 · Cited by 914 · cited 1×
“Heavier and more frequent cannabis use was associated with suicidal ideation and suicide attempts in adolescents and young adults [48, 49].”
Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., Rodriguez, V., Jongsma, H. E., Ferraro, L., La Cascia, C., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30048-3 · Cited by 875 · cited 1×
“A multinational study in Europe and Brazil [50] found that daily use of high potency cannabis increased the risk of psychosis fivefold compared to non-users while daily use of low potency cannabis doubled the risk.”
Self-citationEffects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., Bloomfield, M. A. P., Curran, H. V., & Baler, R. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.3278 · Cited by 867 · cited 2×
“It manifests as a reduce motivation to engage in every-day activities such as a diminished desire to study or work, engage in social or recreational activities people who use cannabis frequently [32].”
Self-citationAcute and Chronic Effects of Cannabinoids on Human Cognition—A Systematic Review
Broyd, S. J., van Hell, H. H., Beale, C., Yücel, M., & Solowij, N. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.002 · Cited by 674 · cited 8×
“Emerging evidence indicates that heavier use, higher doses and higher frequency of cannabis use adversely affect cognition [26, 29].”
InfluentialMacleod, J., Oakes, R., Copello, A., Crome, I., Egger, M., Hickman, M., Oppenkowski, T., Stokes-Lampard, H., & Smith, G. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16200-4 · Cited by 639 · cited 2×
“Early onset of cannabis use ( 15 years of age) and frequent use in early adolescence are associated with lower educational achievement [34–36].”
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617 · cited 1×
“In the laboratory, administration of THC increases psychotic symptoms in people with schizophrenia [53].”
US epidemiology of cannabis use and associated problems
Hasin, D. S. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.198 · Cited by 578 · cited 1×
“In the United States and Canada cannabis legalization has been accompanied by increases in the number of regular users who consume increasingly higher doses of tetrahydrocannabinol (the main psychoactive ingredient in cannabis) [4, 5].”
Gunn, J. K. L., Rosales, C. B., Center, K. E., Nuñez, A., Gibson, S. J., Christ, C., & Ehiri, J. E. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009986 · Cited by 576 · cited 1×
“There is consistent evidence that regular cannabis use during pregnancy increases the risk of maternal anemia and neonatal problems such as reduced birth weight and the need for intensive care treatment [62].”
Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30401-8 · Cited by 564 · cited 1×
“…disorders, e.g. opioid dependence, cannabis use disorder, schizophrenia and schizophrenic psychoses, depressive disorders, post-traumatic stress disorder, anorexia nervosa, Tourette’s syndrome, attention-deficit hyperactivity disorder [99], autism spectrum disorder [100, 101] or dementia [13, 15].”
Self-citationNew trends in cannabis potency in USA and Europe during the last decade (2008–2017)
Chandra, S., Radwan, M. M., Majumdar, C. G., Church, J. C., Freeman, T. P., & ElSohly, M. A. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00983-5 · Cited by 469 · cited 1×
“The higher potency of cannabis products [6], diverse cannabis formulations and modes of administration (e.g., edibles, beverages, vaping, and dabbing) have raised concerns about the adverse public health impacts of cannabis legalization particularly when there is little or no regulatory oversight…”
Self-citationStockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460 · cited 2×
“There is limited and inconsistent evidence that cannabinoids reduce chronic non-cancer pain by at least 30% but not more than 50% [81].”
Self-citationA Systematic Review of the Relationship between High School Dropout and Substance Use
Townsend, L., Flisher, A. J., & King, G. (2007) · Clinical Child and Family Psychology Review · doi:10.1007/s10567-007-0023-7 · Cited by 409
Luijten, M., Schellekens, A. F., Kühn, S., Machielse, M. W. J., & Sescousse, G. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3084 · Cited by 402 · cited 1×
“Mainly driven by striatal dysfunction in the brain, disrupted reward processing is a key characteristic in multiple types of addiction [33].”
Scott, J. C., Slomiak, S. T., Jones, J. D., Rosen, A. F. G., Moore, T. M., & Gur, R. C. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0335 · Cited by 391 · cited 2×
“Emerging evidence indicates that heavier use, higher doses and higher frequency of cannabis use adversely affect cognition [26, 29].”
Leung, J., Chan, G. C. K., Hides, L., & Hall, W. D. (2020) · Addictive Behaviors · doi:10.1016/j.addbeh.2020.106479 · Cited by 358 · cited 2×
“Key risk factors include being male, of younger age [57] and using high-potency cannabis [58].”
Self-citationHall, W., Stjepanović, D., Caulkins, J., Lynskey, M., Leung, J., Campbell, G., & Degenhardt, L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31789-1 · Cited by 357 · cited 1×
“…higher potency of cannabis products [6], diverse cannabis formulations and modes of administration (e.g., edibles, beverages, vaping, and dabbing) have raised concerns about the adverse public health impacts of cannabis legalization particularly when there is little or no regulatory oversight [7].”
Self-citationSchoeler, T., Monk, A., Sami, M. B., Klamerus, E., Foglia, E., Brown, R., Camuri, G., Altamura, A. C., Murray, R., & Bhattacharyya, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00363-6 · Cited by 322 · cited 1×
“A meta-analysis of longitudinal studies [54] found that continued cannabis use in people with psychosis is associated with an increased risk of relapse to psychosis and with longer hospital stays than in non-users [55].”
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303 · cited 1×
“Growing evidence indicates that dysregulation of ECS may contribute to brain dysfunction, psychopathology, neurodevelopmental problems, neurodegenerative diseases, neuroinflammation, among other physiological functions [9, 10].”
Cannabis use and educational achievement: Findings from three Australasian cohort studies
Horwood, L. J., Fergusson, D. M., Hayatbakhsh, M. R., Najman, J. M., Coffey, C., Patton, G. C., Silins, E., & Hutchinson, D. M. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.008 · Cited by 302 · cited 1×
“Early onset of cannabis use ( 15 years of age) and frequent use in early adolescence are associated with lower educational achievement [34–36].”
Nugent, S. M., Morasco, B. J., O'Neil, M. E., Freeman, M., Low, A., Kondo, K., Elven, C., Zakher, B., Motu'apuaka, M., Paynter, R., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0155 · Cited by 301
Assessing the public health impacts of legalizing recreational cannabis use: the US experience
Hall, W., & Lynskey, M. (2020) · World Psychiatry · doi:10.1002/wps.20735 · Cited by 296 · cited 1×
“The past 25 years have seen different policies towards cannabis use for medical or recreational purposes [3].”
Self-citationPsychosocial interventions for cannabis use disorder
Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B., & Gowing, L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005336.pub4 · Cited by 282 · cited 1×
“Psycho-social treatments such as motivational enhancement therapy, cognitive behavioral therapy, and contingency management produce greater reductions in cannabis use than control treatments [60].”
Solmi, M., De Toffol, M., Kim, J. Y., Choi, M. J., Stubbs, B., Thompson, T., Firth, J., Miola, A., Croatto, G., Baggio, F., et al. (2023) · BMJ · doi:10.1136/bmj-2022-072348 · Cited by 271
Cannabis use and psychosis: a review of reviews
Hasan, A., von Keller, R., Friemel, C. M., Hall, W., Schneider, M., Koethe, D., Leweke, F. M., Strube, W., & Hoch, E. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01068-z · Cited by 257 · cited 1×
“Meta-analyses of case–control and cohort studies report a robust association between cannabis use and the risk of a psychotic disorder, and a dose–response relationship between this risk and the frequency of cannabis use [16].”
Self-citationMeiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H.-M., & Baranowski, V. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x167525 · Cited by 214 · cited 1×
“Only one RCT has compared cannabinoids to a guideline medication (ondansetron) for CINV prevention [95] and none compared them to new generation drugs (5-HT3-or NK1 antagonists or neuro-leptics) [94].”
Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence
Hines, L. A., Freeman, T. P., Gage, S. H., Zammit, S., Hickman, M., Cannon, M., Munafo, M., MacLeod, J., & Heron, J. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.1035 · Cited by 208 · cited 1×
“Key risk factors include being male, of younger age [57] and using high-potency cannabis [58].”
Self-citation(2023) · doi:10.18356/9789210028233 · Cited by 204
CALABRIA, B., DEGENHARDT, L., HALL, W., & LYNSKEY, M. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00149.x · Cited by 185 · cited 1×
“Risk of death due to cannabis toxicity is very low, but there is a link between cannabis use at high doses and lethal motor vehicle collisions, cardiac pathophysiology and possibly suicide [17, 77, 78].”
Self-citationHäuser, W., Petzke, F., & Fitzcharles, M. A. (2018) · European Journal of Pain · doi:10.1002/ejp.1118 · Cited by 175 · cited 1×
“Cannabinoids may alleviate neuropathic pain in some patients [82], but there is insufficient evidence for other types of chronic pain [83, 84].”
Unintentional Cannabis Ingestion in Children: A Systematic Review
Richards, J. R., Smith, N. E., & Moulin, A. K. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.07.005 · Cited by 172 · cited 1×
“Overdosing and unintentional cannabis use may cause short term psychiatric, gastrointestinal, and cardiovascular problems in children, teens, and adults [22, 23].”
McCartney, D., Arkell, T. R., Irwin, C., & McGregor, I. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.003 · Cited by 170 · cited 1×
“The concurrent use of cannabis and alcohol produces greater driving impairment than cannabis alone [25].”
Lim, K., See, Y. M., & Lee, J. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.4.301 · Cited by 166 · cited 3×
“…oral cannabinoids) [109] Parkinson’s disease : In 3 out of 4 studies cannabinoids did not improve symptoms or those of l -dopa-induced dyskinesia (CBD, THC/CBD, nabilon, SR141716) [110] Huntington’s chorea : Three small trials (84 participants) tested cannabinoids (CBD, nabilon, nabiximols) [102].”
Pharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156
Nielsen, S., Germanos, R., Weier, M., Pollard, J., Degenhardt, L., Hall, W., Buckley, N., & Farrell, M. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0814-x · Cited by 153 · cited 1×
“Benefits were more evident on patient than on physician ratings of muscle spasticity [91, 92].”
Self-citationOnaemo, V. N., Fawehinmi, T. O., & D'Arcy, C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.043 · Cited by 152 · cited 2×
“Risk of anxiety disorders is twofold higher in people who misuse cannabis, threefold to fourfold higher in those with a CUD [42, 45].”
Sholler, D. J., Schoene, L., & Spindle, T. R. (2020) · Current Addiction Reports · doi:10.1007/s40429-020-00326-8 · Cited by 143 · cited 1×
“CBD is not intoxicating and has fewer safety concerns than THC, but there is the potential for liver toxicity, drug-drug interactions, and there is poor regulatory oversight of CBD products [105].”
Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis
Gurney, J., Shaw, C., Stanley, J., Signal, V., & Sarfati, D. (2015) · BMC Cancer · doi:10.1186/s12885-015-1905-6 · Cited by 137
Júnior, E. A. D. S., Medeiros, W. M. B., dos Santos, J. P. M., de Sousa, J. M. M., da Costa, F. B., Pontes, K. M., Borges, T. C., Segundo, C. E. N., Silva, A. H. A. E., Nunes, E. L. G., et al. (2022) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2021-0396 · Cited by 136
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00984-4 · Cited by 131 · cited 2×
“In these studies, THC and/or CBD were administered with other pharmacotherapies and/or psychotherapy [15].”
Self-citation(2015) · Europe PMC (PubMed Central) · Cited by 126
Cannabis and cannabinoid use in autism spectrum disorder: a systematic review
Júnior, E. A. D. S., Medeiros, W. M. B., Alves, N. T., de Sousa, J. M. M., de Almeida, I. B. C. M., da Costa, F. B., Pontes, K. M., Nunes, E. L. G., da Rosa, M. D., & de Albuquerque, K. L. G. D. (2021) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2020-0149 · Cited by 125
Dellazizzo, L., Potvin, S., Giguère, S., & Dumais, A. (2022) · Addiction · doi:10.1111/add.15764 · Cited by 120
Mammen, G., Rueda, S., Roerecke, M., Bonato, S., Lev-Ran, S., & Rehm, J. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17r11839 · Cited by 118 · cited 2×
“There is strong early evidence that recent cannabis use is associated with negative long-term symptomatic and treatment outcomes across anxiety or mood disorders [46].”
Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis
Ghasemiesfe, M., Ravi, D., Vali, M., Korenstein, D., Arjomandi, M., Frank, J., Austin, P. C., & Keyhani, S. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0522 · Cited by 117 · cited 1×
“There is consistent evidence of an association between acute cannabis smoking and bronchodilation and between regular cannabis smoking and respiratory symptoms of cough, wheezing, and phlegm [65].”
The implementation and public health impacts of cannabis legalization in Canada: a systematic review
Hall, W., Stjepanović, D., Dawson, D., & Leung, J. (2023) · Addiction · doi:10.1111/add.16274 · Cited by 112 · cited 1×
“In the United States and Canada cannabis legalization has been accompanied by increases in the number of regular users who consume increasingly higher doses of tetrahydrocannabinol (the main psychoactive ingredient in cannabis) [4, 5].”
Self-citationAssociations of Suicidality Trends With Cannabis Use as a Function of Sex and Depression Status
Han, B., Compton, W. M., Einstein, E. B., & Volkow, N. D. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.13025 · Cited by 106 · cited 1×
“Heavier and more frequent cannabis use was associated with suicidal ideation and suicide attempts in adolescents and young adults [48, 49].”
Self-citationArterberry, B. J., Treloar Padovano, H., Foster, K. T., Zucker, R. A., & Hicks, B. M. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.11.012 · Cited by 103 · cited 1×
“Increases in cannabis potency have been associated with a faster progression to first onset of symptoms [59].”
Pharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96
Cannabis Use and Car Crashes: A Review
Preuss, U. W., Huestis, M. A., Schneider, M., Hermann, D., Lutz, B., Hasan, A., Kambeitz, J., Wong, J. W. M., & Hoch, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.643315 · Cited by 89 · cited 2×
“Acute cannabis consumption has consistently been associated with a modest increase in the risk of traffic accidents, with odd ratios ranging from 1.25 to 1.97 [17].”
InfluentialSelf-citationBotsford, S. L., Yang, S., & George, T. P. (2020) · The American Journal on Addictions · doi:10.1111/ajad.12963 · Cited by 88 · cited 2×
“Frequent cannabis use was associated with bipolar disorder and greater bipolar symptom severity, such as mania, rapid cycling, and mixed episodes [47].”
Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms
DeVuono, M. V., & Parker, L. A. (2020) · Cannabis & Cannabinoid Research · doi:10.1089/can.2019.0059 · Cited by 87 · cited 1×
“These cyclical episodes occur with prolonged, high-dose cannabis use and are alleviated by hot baths and showers and abstinence from cannabis [74].”
Pacheco-Colón, I., Limia, J. M., & Gonzalez, R. (2018) · Psychology of Addictive Behaviors · doi:10.1037/adb0000380 · Cited by 82 · cited 1×
“There is partial support from longitudinal studies for a causal link between cannabis use and a reduction in motivation, that has been referred to as an “a motivation syndrome” [31].”
The association of cannabis use and cardiac dysrhythmias: a systematic review
Richards, J. R., Blohm, E., Toles, K. A., Jarman, A. F., Ely, D. F., & Elder, J. W. (2020) · Clinical Toxicology · doi:10.1080/15563650.2020.1743847 · Cited by 82 · cited 2×
“There are case reports of adverse cardiovascular risks in chronic cannabis users (e.g., myocardial infarctions, tachycardia, dysrhythmias, hypotension, and orthostatic hypotension) [68–70].”
Petzke, F., Enax-Krumova, E. K., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0089-y · Cited by 80
Association between cannabis use disorder and schizophrenia stronger in young males than in females
Hjorthøj, C., Compton, W., Starzer, M., Nordholm, D., Einstein, E., Erlangsen, A., Nordentoft, M., Volkow, N. D., & Han, B. (2023) · Psychological Medicine · doi:10.1017/s0033291723000880 · Cited by 80 · cited 1×
“More recently, a study based on electronic record over 5 decades in the Danish population reported an increase in the incidence of schizophrenia associated with use of THC and CUD, predominantly among young males 20–30 years of age in whom cannabis use accounted for 30% of the cases [51].”
Self-citationCannabinoids for the treatment of dementia
Kuharić, D. B., Marković, D., Brković, T., Kegalj, M. J., Rubić, Ž., Vuica, A., Jerončić, A., & Puljak, L. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012820.pub2 · Cited by 79
E-cigarette vaping associated acute lung injury (EVALI): state of science and future research needs
Marrocco, A., Singh, D., Christiani, D. C., & Demokritou, P. (2022) · Critical Reviews in Toxicology · doi:10.1080/10408444.2022.2082918 · Cited by 78
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. (2022) · Cochrane Database Systematic Reviews · doi:10.1002/14651858.cd013444.pub2 · Cited by 75
Pearlson, G. D., Stevens, M. C., & D'Souza, D. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.689444 · Cited by 72 · cited 2×
“Measuring THC-related impairment and fitness to drive is more complicated than for alcohol because the absorption and bio-availability of THC does not follow a uniform time-and dose-dependent course and cannabis-related behavioral impairments differ from those of alcohol [24].”
Tafelski, S., Häuser, W., & Schäfer, M. (2016) · Der Schmerz · doi:10.1007/s00482-015-0092-3 · Cited by 71 · cited 2×
“As an adjuvant treatment, they showed higher antiemetic effects than placebo or conventional anti-emetics [94].”
Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis
Bahji, A., Meyyappan, A. C., & Hawken, E. R. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719892717 · Cited by 70 · cited 1×
“…the use of cannabinoid for dystonia [102, 110] Dementia : There is uncertain evidence for the efficacy and tolerability of cannabinoids in dementia [111, 112] Gastrointestinal disorders : No firm conclusions could be drawn on the benefits and side effects of cannabinoids in adults with active…”
Johnson, R. M., LaValley, M., Schneider, K. E., Musci, R. J., Pettoruto, K., & Rothman, E. F. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.01.012 · Cited by 69 · cited 1×
“Risk of physical dating violence, victimization and perpetration is increased in female adolescent cannabis users and higher among alcohol users [39].”
Patel, R. S., Kamil, S. H., Bachu, R., Adikey, A., Ravat, V., Kaur, M., Tankersley, W. E., & Goyal, H. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.08.003 · Cited by 67
Cannabis for the treatment of Crohn's disease
Kafil, T. S., Nguyen, T. M., MacDonald, J. K., & Chande, N. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012853.pub2 · Cited by 66
Talwar, A., Estes, E., Aparasu, R., & Reddy, D. S. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114238 · Cited by 66
Xue, S., Husain, M. I., Zhao, H., & Ravindran, A. V. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720952251 · Cited by 65
Twomey, C. D. (2017) · Journal of Epidemiology and Community Health · doi:10.1136/jech-2016-208145 · Cited by 62 · cited 2×
“Regular cannabis use is associated with anxiety symptoms [41] and increased risk of anxiety disorders particularly during the withdrawal stage [43].”
The Behavioral Sequelae of Cannabis Use in Healthy People: A Systematic Review
Sorkhou, M., Bedder, R. H., & George, T. P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.630247 · Cited by 61 · cited 2×
“Regular cannabis use is associated with more depressive symptoms, and heavy cannabis use by youth and young adults predicts an increased risk of major depression [41]; twofold for cannabis misusers and threefold to fivefold for people with a CUD [42].”
Lemyre, A., Gauthier-Légaré, A., & Bélanger, R. E. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1536882 · Cited by 59 · cited 1×
“Emerging evidence found a non-significant association between chronic cannabis consumption and social anxiety disorders [44, 45] and another study showed that cannabis use did not impede recovery from panic disorder’ when treated with other medications or treatments [46].”
Dawson, D., Stjepanović, D., Lorenzetti, V., Cheung, C., Hall, W., & Leung, J. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111263 · Cited by 57
Self-citationDellazizzo, L., Potvin, S., Dou, B. Y., Beaudoin, M., Luigi, M., Giguère, C.-É., & Dumais, A. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19101008 · Cited by 55
Gillespie, N. A., & Kendler, K. S. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3564 · Cited by 54 · cited 1×
“Triangulation of evidence from genetically sensitive research designs [52] indicates that the observed association may reflect in part a causal effect of cannabis use on schizophrenia.”
Cannabis for the treatment of Crohn's disease
Kafil, T. S., Nguyen, T. M., MacDonald, J. K., & Chande, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012853 · Cited by 53
Cannabis and Anxiety: A Critical Review
Beletsky, A., Liu, C., Lochte, B., Samuel, N., & Grant, I. (2024) · Medical Cannabis and Cannabinoids · doi:10.1159/000534855 · Cited by 53
A Systematic Review of the Neurocognitive Effects of Cannabis Use in Older Adults
Scott, E. P., Brennan, E., & Benitez, A. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00285-9 · Cited by 48 · cited 2×
“There is preliminary evidence of cognitive impulsivity and poorer verbal memory and visual recognition in older studies of recreational users [28].”
Cannabis for the treatment of ulcerative colitis
Kafil, T. S., Nguyen, T. M., MacDonald, J. K., & Chande, N. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012954.pub2 · Cited by 47
Long-term effects of prenatal cannabis exposure: Pathways to adolescent and adult outcomes
De Genna, N. M., Willford, J. A., & Richardson, G. A. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173358 · Cited by 46 · cited 1×
“There is limited evidence that some problems may persist into adulthood, such as delin-quency, substance use and abuse, memory deficits, and psychotic symptoms [64].”
Cannabinoids in Glaucoma Patients: The Never-Ending Story
Passani, A., Posarelli, C., Sframeli, A. T., Perciballi, L., Pellegrini, M., Guidi, G., & Figus, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123978 · Cited by 45
Doeve, B. H., van de Meeberg, M. M., van Schaik, F. D. M., & Fidder, H. H. (2020) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001393 · Cited by 44
Baranger, D. A. A., Paul, S. E., Colbert, S. M. C., Karcher, N. R., Johnson, E. C., Hatoum, A. S., & Bogdan, R. (2022) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2022.3191 · Cited by 42
Vaughn, S., Strawn, J., Poweleit, E., Sarangdhar, M., & Ramsey, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070615 · Cited by 40 · cited 1×
“THC and/or CBD increase SSRI concentrations in adolescents, and coadministration of CBD and SSRIs increases the risk of cough, diarrhea, dizziness, and fatigue [106].”
The Basic Science of Cannabinoids
Sideris, A., Lauzadis, J., & Kaczocha, M. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006472 · Cited by 40 · cited 1×
“We have also seen a rapid development in the basic science of cannabinoids, including characterization and function of the endocannabinoid system (ECS) in the human brain and other organs, the pharmacology of cannabinoids, and therapeutic cannabinoid development [8].”
Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials
Longo, R., Oudshoorn, A., & Befus, D. (2021) · Pain Management Nursing · doi:10.1016/j.pmn.2020.11.006 · Cited by 39 · cited 1×
“There is weak evidence for patient-perceived benefits [85].”
Schmid, Y., Scholz, I., Mueller, L., Exadaktylos, A. K., Ceschi, A., Liechti, M. E., & Liakoni, E. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107726 · Cited by 38 · cited 2×
“Cannabis can cause recurring bouts of nausea, vomiting and intense abdominal pain amidst other acute gastrointestinal symptoms that are severe enough to prompt users to seek medical help [23].”
Cannabis and Autoimmunity: Possible Mechanisms of Action
Giorgi, V., Marotto, D., Batticciotto, A., Atzeni, F., Bongiovanni, S. F., & Sarzi‐Puttini, P. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s267905 · Cited by 38 · cited 1×
“Due to the role of the ECS in modulating inflammation, there is considerable interest in the therapeutic potential of cannabinoids in the treatment of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease [103].”
A Review of Cases of Marijuana and Violence
Miller, N. S., Ipeku, R., & Oberbarnscheidt, T. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17051578 · Cited by 36 · cited 1×
“The risk of physical violence is increased in regular cannabis users, especially in those with severe mental disorders [37, 38].”
Power, E., Sabherwal, S., Healy, C., O’ Neill, A., Cotter, D., & Cannon, M. (2021) · Psychological Medicine · doi:10.1017/s0033291720005036 · Cited by 34 · cited 1×
“There is mixed evidence on the effects of the age of first cannabis use and duration of use on cognitive performance, except for IQ, which decreased by 2 points each year after the start of frequent/dependent use [30].”
Velayudhan, L., McGoohan, K. L., & Bhattacharyya, S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.35913 · Cited by 33 · cited 1×
“THC-based products may alter thinking and perception, produce dizziness, lighthead-edness and sedation particularly in older adults [104].”
Can cannabis kill? Characteristics of deaths following cannabis use in England (1998–2020)
Rock, K. L., Englund, A., Morley, S., Rice, K., & Copeland, C. S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221115760 · Cited by 32 · cited 1×
“Risk of death due to cannabis toxicity is very low, but there is a link between cannabis use at high doses and lethal motor vehicle collisions, cardiac pathophysiology and possibly suicide [17, 77, 78].”
Athanassiou, M., Dumais, A., Gnanhoue, G., Abdel-Baki, A., Jutras-Aswad, D., & Potvin, S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1942845 · Cited by 29
Akgün, K., Essner, U., Seydel, C., & Ziemssen, T. (2019) · Journal of Central Nervous System Disease · doi:10.1177/1179573519831997 · Cited by 28 · cited 1×
“Benefits were more evident on patient than on physician ratings of muscle spasticity [91, 92].”
Nonmedical Marijuana Use and Cardiovascular Events: A Systematic Review
Yang, P. K., Odom, E. C., Patel, R., Loustalot, F., & Coleman King, S. (2022) · Public Health Reports® · doi:10.1177/0033354920988285 · Cited by 28
A provisional evaluation of Australia's medical cannabis program
Graham, M., Chiu, V., Stjepanović, D., & Hall, W. (2023) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2023.104210 · Cited by 28 · cited 1×
“An overview of adverse events reported in medicinal cannabis studies, medicinal cannabis product information, and post-marketing adverse event data can be found elsewhere [108].”
Self-citationA Large-Scale Naturalistic Examination of the Acute Effects of Cannabis on Pain.
Cuttler, C., LaFrance, E. M., & Craft, R. M. (2022) · Cannabis & Cannabinoid Research · doi:10.1089/can.2020.0068 · Cited by 25 · cited 1×
“There is also evidence that tolerance to the analgesic effects of cannabinoids develops with repeated use, which might limit their long-term benefits [89].”
Cannabinoids for the treatment of dementia
Marković, D., Bošnjak, D., Brković, T., Jerić, M., Rubić, Ž., Vuica, A., & Puljak, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012820 · Cited by 21
Effects of Cannabis on Cardiovascular System: The Good, the Bad, and the Many Unknowns
Dabiri, A. E., & Kassab, G. S. (2021) · Medical Cannabis and Cannabinoids · doi:10.1159/000519775 · Cited by 21 · cited 1×
“The endogenous cannabinoid system may also provide an array of potential benefits, particularly in the role of CBD as a neuroprotector for stroke [73].”
Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations
Chang, Y., Zhu, M., Vannabouathong, C., Mundi, R., Chou, R. S., & Bhandari, M. (2021) · Pain Research and Management · doi:10.1155/2021/8857948 · Cited by 20 · cited 1×
“Cannabinoids are recommended as second or third-line medications for chronic pain [87].”
Wirksamkeit und Sicherheit von Cannabisarzneimitteln: Ergebnisse der CaPRis-Studie
CaPRis-Projektgruppe, Hoch, E., Friemel, C. M., Schneider, M., Pogarell, O. M., Hasan, A., & Preuss, U. W. (2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-02965-3 · Cited by 18
Self-citationCannabis-based medicinal products: summary of NICE guidance
Chang-Douglass, S., Mulvihill, C., & Pilling, S. (2020) · BMJ · doi:10.1136/bmj.m1108 · Cited by 18 · cited 2×
“Nabiximols are only recommended if other treatments are ineffective, and a 4-week trial produces at least a 20% reduction in spasticity-related symptoms [88].”
Lorenzetti, V., Kowalczyk, M., Duehlmeyer, L., Greenwood, L.-M., Chye, Y., Yücel, M., Whittle, S., & Roberts, C. A. (2023) · Cannabis & Cannabinoid Research · doi:10.1089/can.2021.0099 · Cited by 17 · cited 1×
“These alterations were more consistently observed in persons with a history of chronic cannabis use [76].”
Self-citationAndrzejewski, K. L., Barbano, R. L., & Mink, J. W. (2016) · Basal Ganglia · doi:10.1016/j.baga.2016.06.001 · Cited by 14 · cited 2×
“…oral cannabinoids) [109] Parkinson’s disease : In 3 out of 4 studies cannabinoids did not improve symptoms or those of l -dopa-induced dyskinesia (CBD, THC/CBD, nabilon, SR141716) [110] Huntington’s chorea : Three small trials (84 participants) tested cannabinoids (CBD, nabilon, nabiximols) [102].”
Johnson, S., Ziegler, J., & August, D. A. (2021) · Nutrition in Clinical Practice · doi:10.1002/ncp.10639 · Cited by 14 · cited 1×
“In cancer anorexia cachexia syndrome patients’ cannabinoid treatment did not significantly improve appetite, oral intake, or anorexia-related quality of life [96].”
AminiLari, M., Kithulegoda, N., Strachan, P., MacKillop, J., Wang, L., Pallapothu, S., Neumark, S., Sharma, S., Sethi, J., Zacharias, R., et al. (2022) · Pain Medicine · doi:10.1093/pm/pnac085 · Cited by 14
Cannabis, Cannabinoids, and Stroke: Increased Risk or Potential for Protection—A Narrative Review
Carter, C., Laviolette, L., Bietar, B., Zhou, J., & Lehmann, C. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040196 · Cited by 13 · cited 2×
“Rigorous studies supporting these positive effects are missing [72].”
Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy
Patel, J. D., Wang, A. Y.-D., Naidu, S. S., Frishman, W. H., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000620 · Cited by 7
Cardiovascular Effects of Cannabinoids
Wang, A., Dey, S., Subhan, S., Patel, J., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000566 · Cited by 6
Research works printed but not linked: 1
- Hoch E, Friemel C, Schneider M (2019) Cannabis: benefits and risks. Springer, Heidelberg
Cited by
The adverse public health effects of non-medical cannabis legalisation in Canada and the USA
Mekonen, T., Hoch, E., Fischer, B., Dawson, D., & Hall, W. (2025) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00299-8 · Cited by 51
Self-citationWilson, J., Dobson, O., Langcake, A., Mishra, P., Bryant, Z., Leung, J., Dawson, D., Graham, M., Teesson, M., Freeman, T. P., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00015-5 · Cited by 48
“However, few reviews included evidence for the treatment of all mental disorders and SUDs as the primary indication, 10,11 conducted metaanalyses, 11,14 critically evaluated the risk of bias and quality of evidence, 13,14 or examined the evidence according to the type of cannabinoid.”
Self-citationRamer, R., & Hinz, B. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108851 · Cited by 18
Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges
Sič, A., George, C., Gonzalez, D. F., Tseriotis, V., & Knežević, N. N. (2025) · Neurology International · doi:10.3390/neurolint17090141 · Cited by 16
“Rates of dizziness reach 25%, drowsiness 8%, and disorientation 4%, with up to 12% of patients discontinuing treatment due to side effects [76,77].”
Acute cannabis intoxication among the paediatric population
Malta, G., Albano, G. D., Lavanco, G., Brancato, A., Cannizzaro, C., Argo, A., Contorno, S., Plescia, F., & Zerbo, S. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1558721 · Cited by 19
Metadata
- Authors
- Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W.
- Affiliations
- LMU Klinikum (DE)
- National Institute on Alcohol Abuse and Alcoholism (US)
- IFT Institut für Therapieforschung (DE)
- Australian Catholic University (AU)
- University of Bath (GB)
- The University of Queensland (AU)
- Corresponding author
- Hoch, E.
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2024-09-19
- Volume
- 275
- Issue
- 2
- Pages
- 281-292
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- PMC
- PMC11910417
- OpenAlex
- W4402698048
- Semantic Scholar
- 04009c33b5339cffb27ec4198594652c85a4294d
- Cited by
- 139
- References
- 119
- Citations by year
- 2026: 86 · 2025: 52 · 2024: 1
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
- Funders
- Klinikum der Universität München
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- cannabis, cannabinoids, delta-9-tetrahydrocannabinol, recreational cannabis use, medical cannabis, cannabis use disorder, adolescent cannabis use, psychosis, schizophrenia, cognitive impairment, prenatal cannabis exposure, cannabidiol, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, cannabis legalization
- MeSH terms
- Cannabinoids, Cannabis, Marijuana Abuse, Humans, Dronabinol, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.